Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52849
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMichele W. Tangen_US
dc.contributor.authorSoo Yon Rheeen_US
dc.contributor.authorSilvia Bertagnolioen_US
dc.contributor.authorNathan Forden_US
dc.contributor.authorSusan Holmesen_US
dc.contributor.authorKim C. Sigaloffen_US
dc.contributor.authorRaph L. Hamersen_US
dc.contributor.authorTobias F.Rinke De Witen_US
dc.contributor.authorHerve J. Fleuryen_US
dc.contributor.authorPhyllis J. Kankien_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.authorClaudia A. Hawkinsen_US
dc.contributor.authorCarole L. Wallisen_US
dc.contributor.authorWendy Stevensen_US
dc.contributor.authorGert U. Van Zylen_US
dc.contributor.authorWeerawat Manosuthien_US
dc.contributor.authorMina C. Hosseinipouren_US
dc.contributor.authorNicole Ngo-Giang-Huongen_US
dc.contributor.authorLaurent Belecen_US
dc.contributor.authorMartine Peetersen_US
dc.contributor.authorAvelin Aghokengen_US
dc.contributor.authorTorsak Bunupuradahen_US
dc.contributor.authorSherri Burdaen_US
dc.contributor.authorPatricia Caneen_US
dc.contributor.authorGiulia Cappellien_US
dc.contributor.authorCharlotte Charpentieren_US
dc.contributor.authorAnoumou Y. Dagnraen_US
dc.contributor.authorAlaka K. Deshpandeen_US
dc.contributor.authorZiad El-Katiben_US
dc.contributor.authorSusan H. Eshlemanen_US
dc.contributor.authorJoseph Fokamen_US
dc.contributor.authorJean Chrysostome Godyen_US
dc.contributor.authorDavid Katzensteinen_US
dc.contributor.authorDonato D. Koyaltaen_US
dc.contributor.authorJohnstone J. Kumwendaen_US
dc.contributor.authorMarc Lallemanten_US
dc.contributor.authorLutgarde Lynenen_US
dc.contributor.authorVincent C. Marconien_US
dc.contributor.authorNicolas A. Margoten_US
dc.contributor.authorSandrine Moussaen_US
dc.contributor.authorThumbi Ndung'Uen_US
dc.contributor.authorPhillipe N. Nyambien_US
dc.contributor.authorCatherine Orrellen_US
dc.contributor.authorJonathan M. Schapiroen_US
dc.contributor.authorRob Schuurmanen_US
dc.contributor.authorSunee Sirivichayakulen_US
dc.contributor.authorDavey Smithen_US
dc.contributor.authorMaria Zolfoen_US
dc.contributor.authorMichael R. Jordanen_US
dc.contributor.authorRobert W. Shaferen_US
dc.date.accessioned2018-09-04T09:33:27Z-
dc.date.available2018-09-04T09:33:27Z-
dc.date.issued2013-06-15en_US
dc.identifier.issn00221899en_US
dc.identifier.other2-s2.0-84878329003en_US
dc.identifier.other10.1093/infdis/jit114en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84878329003&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/52849-
dc.description.abstractBackground The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available in resource-limited settings, it is critical to identify the cross-resistance patterns associated with first-line stavudine failure.MethodsWe analyzed HIV-1 resistance mutations following first-line stavudine failure from 35 publications comprising 1,825 individuals. We also assessed the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.ResultsMutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals. Mutations with preferential tenofovir activity, ≥two thymidine analog mutations (TAMs) or Q151M, occurred in 22% of individuals. Nevirapine increased the risk of TAMs, K65R, and Q151M. Longer therapy increased the risk of TAMs and Q151M but not K65R. Subtype C and CRF01-AE increased the risk of K65R, but only CRF01-AE increased the risk of K65R without Q151M.ConclusionsRegardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was more likely than zidovudine to retain antiviral activity following first-line d4T therapy. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.en_US
dc.subjectMedicineen_US
dc.titleNucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudineen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of Infectious Diseasesen_US
article.volume207en_US
article.stream.affiliationsStanford Universityen_US
article.stream.affiliationsOrganisation Mondiale de la Santeen_US
article.stream.affiliationsAcademic Medical Centre, University of Amsterdamen_US
article.stream.affiliationsCHU Hopitaux de Bordeauxen_US
article.stream.affiliationsHarvard School of Public Healthen_US
article.stream.affiliationsChulalongkorn Universityen_US
article.stream.affiliationsNorthwestern Universityen_US
article.stream.affiliationsLancet Laboratoriesen_US
article.stream.affiliationsUniversity of Witwatersranden_US
article.stream.affiliationsUniversiteit Stellenboschen_US
article.stream.affiliationsThailand Ministry of Public Healthen_US
article.stream.affiliationsKamuzu Central Hospitalen_US
article.stream.affiliationsInstitute of research for development, Thailanden_US
article.stream.affiliationsUniversite Paris Descartesen_US
article.stream.affiliationsIRD Centre de Montpellieren_US
article.stream.affiliationsInstitut de Recherche pour le Developpement Cameroonen_US
article.stream.affiliationsThai Red Cross AIDS Research Centreen_US
article.stream.affiliationsNYU School of Medicineen_US
article.stream.affiliationsHealth Protection Agencyen_US
article.stream.affiliationsChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Managementen_US
article.stream.affiliationsConsiglio Nazionale delle Ricercheen_US
article.stream.affiliationsUniversite Paris 7- Denis Dideroten_US
article.stream.affiliationsFMMP/ULen_US
article.stream.affiliationsSir Jamsetjee Jeejebhoy Group of Hospitalsen_US
article.stream.affiliationsMcGill Universityen_US
article.stream.affiliationsKarolinska Instituteten_US
article.stream.affiliationsThe Johns Hopkins School of Medicineen_US
article.stream.affiliationsUniversite de Yaounde Ien_US
article.stream.affiliationsFaculté des Sciences de la Santé Banguien_US
article.stream.affiliationsComplexe Pédiatrique Banguien_US
article.stream.affiliationsHôpital Général de Référence Nationaleen_US
article.stream.affiliationsUniversity of Malawien_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsPrins Leopold Instituut voor Tropische Geneeskundeen_US
article.stream.affiliationsEmory University School of Medicineen_US
article.stream.affiliationsRollins School of Public Healthen_US
article.stream.affiliationsGilead Sciences Incorporateden_US
article.stream.affiliationsInstitut Pasteur de Banguien_US
article.stream.affiliationsUniversity of KwaZulu-Natalen_US
article.stream.affiliationsNew York Universityen_US
article.stream.affiliationsVA Medical Centeren_US
article.stream.affiliationsUniversity of Cape Townen_US
article.stream.affiliationsNational Hemophilia Centeren_US
article.stream.affiliationsUniversity Medical Center Utrechten_US
article.stream.affiliationsUniversity of California, San Diegoen_US
article.stream.affiliationsTufts University School of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.